K. Anderson

发表

Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications

D. Chauhan, K. Anderson, 2003, Apoptosis.

LEADING ARTICLE International uniform response criteria for multiple myeloma

M. Beksac, B. Barlogie, G. Morgan, 2006 .

Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104

K. Owzar, C. Hofmeister, R. Vij, 2015 .

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

D. Keskin, N. Munshi, N. Munshi, 2018, Leukemia.

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

M. Amiot, J. Opferman, Jing Zhang, 2008, Oncogene.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

P. Elliott, P. Richardson, D. Chauhan, 2001, Cancer research.

Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.

K. Owzar, C. Hofmeister, V. Hárs, 2010 .

LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo.

N. Munshi, P. Richardson, N. Mitsiades, 2002 .

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, D. Siegel, P. Richardson, 2014, Blood Cancer Journal.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, D. Siegel, P. Richardson, 2014, Blood Cancer Journal.

Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells*

John Calvin Reed, S. Kharbanda, D. Chauhan, 2001, The Journal of Biological Chemistry.

Expressed fusion gene landscape and its impact in multiple myeloma

G. Parmigiani, N. Munshi, M. Samur, 2017, Nature Communications.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

U. Mellqvist, M. Dimopoulos, H. Einsele, 2016, Leukemia.

Apoptosis in multiple myeloma: Therapeutic implications

D. Chauhan, K. Anderson, 2001, Apoptosis.

Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)

P. Richardson, S. Treon, I. Ghobrial, 2008 .

A242 Vorinostat and Bortezomib in Relapsed/Refractory MM

S. Jagannath, D. Siegel, V. Richon, 2009 .

A241 Vorinostat/Lenalidomide/Dexamethasone: A Phase I Study

D. Siegel, P. Richardson, C. Mitsiades, 2009 .

Clinical and biological significance of microRNA profiling in patients with myeloma.

N. Munshi, H. Avet-Loiseau, S. Amin, 2009, Journal of Clinical Oncology.

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

B622 Rho-A and Rac-1 GTPases in Multiple Myeloma

Charles P. Lin, Melhem, A. Roccaro, 2009 .

Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

S. Jagannath, S. Singhal, P. Richardson, 2008 .

Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma

S. Jagannath, P. Richardson, J. Zeldis, 2008 .

Use of high-density SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma

N. Munshi, Cheng Li, P. Moreau, 2008 .